Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy

Fig. 4

(A) HMGB1 and COX-2 protein expressions in 4T1 tumor cells analyzed by western blot (a) and quantified via Image J software (b) after treatment with different formulations. **p < 0.01 (GEM-CXB NPs vs. Saline), ※※p < 0.01 (GEM&CXB vs. Saline or GEM or CXB), ※p < 0.05 (GEM-CXB NPs vs. GEM&CXB). (B) The secretion level of PGE2 in 4T1 tumor cells treated with different formulations analyzed by ELISA kit. (C, E) Quantitative analysis of the percentage of CD40 and CCR7 (I) after different treatments. (D) The CRT exposure on 4T1 tumor cells treated with different formulations observed by inverted fluorescence microscope. Flow cytometry analysis of CD4+ (F) and CD8+ (G) T cell proliferation after co-culture of MDSCs and CFSE-labeled splenocytes with different formulations-treatment

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us